Cancer cells reprogram their metabolism to meet increased biosynthetic demands, commensurate with elevated rates of replication. Pyruvate kinase M2 (PKM2) catalyzes the final and rate-limiting step in tumor glycolysis, controlling the balance between energy production and the synthesis of metabolic precursors. We report here the synthesis and evaluation of a positron emission tomography (PET) radiotracer, [ 11 C]DASA-23, that provides a direct noninvasive measure of PKM2 expression in preclinical models of glioblastoma multiforme (GBM). In vivo, orthotopic U87 and GBM39 patient-derived tumors were clearly delineated from the surrounding normal brain tissue by PET imaging, corresponding to exclusive tumor-associated PKM2 expression. In addition, systemic treatment of mice with the PKM2 activator TEPP-46 resulted in complete abrogation of the PET signal in intracranial GBM39 tumors. Together, these data provide the basis for the clinical evaluation of imaging agents that target this important gatekeeper of tumor glycolysis.
INTRODUCTION
Tumors undergo metabolic reprogramming to support the synthesis of new macromolecules required for rapid cell division, which also provides a selective advantage for progression and protection from cell death (1) . The concept of metabolic adaptation in tumors was first described by Otto Warburg in the 1920s after the discovery that cancer cells display increased rates of glucose utilization in comparison to normal tissue, even under aerobic conditions (2) . We now know that the metabolic transformation of cancer cells encompasses multiple interconnecting metabolic networks (3, 4) , with feedback loops and crosstalk acting to provide plasticity and help the cells survive the steep and localized nutrient and oxygen gradients present in the harsh tumor microenvironment (5) .
Central to tumor metabolism is the glycolytic pathway, which sustains tumors through the generation of ATP and synthesis of intermediates for biosynthetic reactions. Pyruvate kinase (PK) catalyzes the final and rate-limiting reaction in glycolysis, converting phosphoenolpyruvate (PEP) to pyruvate by transferring the high-energy phosphate group to adenosine diphosphate (ADP) to produce adenosine triphosphate (ATP). PK consists of four isoforms, of which the spliced variant PKM2 is preferentially expressed in all cancers studied to date, regardless of their tissue of origin (6) . PKM2 is allosterically regulated by the stabilization of a highly active tetramer relative to monomeric/ dimeric PKM2. The tetramer of PKM2 has a high affinity for PEP, favoring synthesis of ATP and pyruvate, whereas the monomer/dimer has reduced activity because of its low affinity for PEP at physiological concentrations (7) . When PKM2 is in the monomeric/dimeric conformation, reduced glycolytic flux through pyruvate results in the accumulation of precursors for the biosynthesis of amino acids, nucleic acids, and phospholipids, commensurate with the production of reducing power through pentose phosphate pathway-derived NADPH (reduced form of nicotinamide adenine dinucleotide phosphate) (8) . A dynamic equilibrium between the two states of PKM2 enables tumor cells to switch between anabolic and catabolic metabolism (Fig. 1 ). Alternative splicing of PKM2 is controlled by c-Myc and HIF-1 oncogenes [reviewed in (9) ], with quaternary structure of PKM2 tightly regulated by the glycolytic intermediate fructose 1,6-bisphosphate (FBP) (10) and growth factor signaling (11) . In recent years, PKM2 has been targeted for cancer therapy through the development of small-molecule activators that promote tetramer formation (12, 13) .
Given the importance of PKM2 in the regulation of tumor metabolism, we sought to noninvasively measure its expression through the development of a PKM2-specifc radiopharmaceutical. A class of N,N-diarylsulfonamides (DASA) was reported by Boxer et al. as highly promising PKM2 activators (12) , known to promote PKM2 tetramer formation through binding at the subunit interaction interface of the PKM2 dimer in an allosteric pocket distinct from the binding site of FBP, and to inhibit tumor growth in vivo (14) . Here, we report the synthesis and evaluation of a positron emission tomography (PET) radiotracer for dimeric PKM2, [ 11 C]DASA-23, based on this class of compounds ( Fig. 2A) . DASA-23 was selected as a suitable candidate for 11 C labeling because of its high potency as a PKM2 activator [maximum activating concentration (AC 50 ) = 90 nM (12) ], favorable selectivity for PKM2 compared to other PK isozymes [PKM1, PKR, and PKL (12) ] through reversible binding, and the presence of a methoxy moiety, which allows K m (Michaelis constant) for PEP while maintaining PKM2's affinity for ADP, akin to the action of FBP (12 Fig. 2A) , with a radiochemical yield of 2.4 ± 0.8%, >99% radiochemical purity, and a specific activity of 159.2 ± 94.3 GBq/mmol at the end of synthesis (n = 12). The identity of the radiochemistry precursor and cold standard was confirmed through mass spectrometry and nuclear magnetic resonance (NMR) spectroscopy, and the identity of the radiotracer ([ 11 C]DASA-23) was confirmed by high-performance liquid chromatography (HPLC) via co-injection with cold standard (figs. S1 to S3). In cell studies, addition of [ 11 C]DASA-23 resulted in rapid and extensive cellular uptake in both HeLa and U87 tumor cells, reaching 14.9 ± 2.0% radioactivity/mg protein and 19.6 ± 2.0% radioactivity/mg protein, respectively, by 30 min (Fig. 2, B and C) . Removal of exogenous radioactivity resulted in the efflux of cell-associated activity, with~40% of the initial intracellular radioactivity retained 30 min after removal of exogenous [ 11 C]DASA-23 for both cell lines (Fig. 2, B and C).
Retention of [
11 C]DASA-23 is closely correlated to PKM2 expression To determine the specificity of [ 11 C]DASA-23 in cancer cells, we modulated PKM2 protein expression in culture through small inhibitory RNA (siRNA). HeLa cells were selected because of their relative ease of transfection. Knockdown of PKM2 was observed at 48 hours after addition of PKM2 siRNA (siPKM2), with nearly complete protein ablation detected by 72 hours (Fig. 3A) . Extended incubation of cells in culture medium in the presence of scrambled, nontargeting siRNA (siCtrl) induced a temporal increase in PKM2 protein expression. Low levels of PKM1 were measured in naïve cells and, 72 hours after transfection, with either siPKM2 or siCtrl ( fig. S4 ). Next, we compared cell Fig. 1 . Schematic illustrating the control of normal and tumor cell glycolysis by PKM2. PK catalyzes the final step of glycolysis, resulting in net ATP synthesis through the dephosphorylation of PEP. The PKM2 isozyme predominates in proliferating nontumor and tumor cells. Two quaternary PKM2 conformations exist as homodimeric or homotetrameric forms (shown above as two orange spheres and four orange spheres, respectively). Dimeric PKM2 has reduced affinity for PEP in comparison to the tetramer, with tumor PKM2 mainly present in the dimeric form. The reduced conversion of PEP to pyruvate results in a buildup of glycolytic precursors that can be subsequently used by alternative pathways for the biosynthesis of cellular macromolecules. Conversely, PKM2 is mostly present in the tetrameric form in nontumor cells. (Fig. 4A) . Ex vivo biodistribution studies corroborated the PET imaging data (Fig. 4B) . Notably, low [ 11 C]DASA-23 radioactivity was present in the brain 60 min after injection, at 0.86 ± 0.09% of the injected dose per gram of tissue (ID/g). At this time point, U87 tumor uptake was 1.78 ± 0.23% ID/g (n = 4 animals), and the tumor-to-blood, tumor-to-muscle, and tumor-tobrain ratios were 1.1, 1.6, and 2.1, respectively. Additionally, [ 11 C]DASA-23 showed excellent stability in plasma ex vivo, with >96% of the parent compound remaining after 60 min (Fig. 4C) .
Dynamic [
11 C]DASA-23 PET imaging confirmed rapid liver and kidney uptake, followed by clearance through the bladder and small intestine (Fig. 4, D and E) . Rapid tumor uptake of [ 11 C]DASA-23, peaking at 10 min, preceded a slow washout of radioactivity over the remaining 50 min (Fig. 4F) . Muscle uptake of [ 11 C]DASA-23 followed a similar pattern of retention but at lower levels. This was contrasted with [ 11 C]DASA-23 uptake in the brain, where high initial delivery, peaking 30 s after injection (13.4 ± 1.9% ID/g), was followed by rapid clearance, reaching low steady-state levels (2.3 ± 0.2% ID/g) by 10 min after injection. Fig. 5A ; the corresponding threedimensional (3D) movie is displayed as movie S1, with a non-tumor-bearing mouse shown in movie S2 for comparison]. Similarly to subcutaneous xenograft tumors, U87 tumor kinetics were characterized by rapid initial uptake preceding slow washout. In comparison, radioactivity from the control, contralateral region of the brain reached similar levels of radiotracer delivery (P > 0.05; fig. S5 ), but it was not retained (Fig. 5B) . Time course images of initial [ (Fig. 5D ). Contrast-enhancing U87 tumors, clearly defined in the T 1 -weighted images, excellently matched the corresponding microPET images. It is important to note that the trace amount of [ 11 C]DASA-23 (~200 pmol) used here was~15,000× lower than the amount used in previous drug studies (~3 mmol) (14) .
After imaging, the brains of tumor-bearing mice were excised for analysis by histopathology. H&E staining confirmed excellent correlation of PET signal intensity with histopathological findings (Fig. 5E ). The PET signal of orthotopic U87 tumors was sharply delineated from the surrounding brain tissue (Fig. 5D ), matching the pattern of cytosolic PKM2 expression shown in tissue sections ( Fig. 5E and fig. S7 ). PKM1 expression was exclusively located in the normal healthy brain and absent from the intracranial tumors ( Having previously demonstrated the specificity of [
11 C]DASA-23 for the detection of PKM2 in cell culture (Fig. 3) , we determined whether the PET signal originating from the intracranial tumors in vivo corresponded to tumor-specific PKM2 expression. The short half-life of carbon-11 permitted the use of the same mice in longitudinal studies, where [ 11 C]DASA-23 tumor uptake was assessed at baseline and subsequently after challenge with a blocking agent, 24 hours after initial evaluation. A structurally distinct PKM2 activator, TEPP-46, a highly selective PKM2 activator that binds with nanomolar affinity (16) , was selected to test the specificity of [ 
DISCUSSION
Tumor cells reprogram their metabolism in response to the increased anabolic and catabolic demands of highly proliferative cells. For many metabolic pathways, the balance between biomolecular synthesis and energy production is highly regulated. An elegant example is the case of acetyl-CoA (coenzyme A) carboxylase, which controls the opposing rates of fatty acid synthesis and b-oxidation on the basis of intracellular concentrations of acetyl-CoA and malonyl-CoA (17) . Altered tumor glycolysis is mediated, in part, by PKM2 through transcriptional and epigenetic means (18) (19) (20) , with a growing body of evidence demonstrating a critical role of PKM2 in tumorigenesis and progression (6) . Further evidence suggests that PKM2 might provide a similar regulatory switch to acetyl-CoA carboxylase: controlling the balance between glycolytically derived anabolic and catabolic metabolism (8, 11, 21, 22) . PKM2 has also been shown to translocate to the nucleus, where it functions to promote cell proliferation through interaction with HIF, STAT3, Oct4, and b-catenin [reviewed in (9) ].
Clinically relevant imaging agents and modalities for the direct, noninvasive imaging of PKM2 are a topic of great interest and importance. PKM2 is overexpressed in tumors (6) and expressed in most tissues to varying degrees, with the exception of adult muscle, brain, and liver (23) (24) (25) . Given the intrinsically low background of PKM2 in the brain, we asked whether PKM2 is up-regulated in transformed human glioblastoma cells, evaluated in orthotopic mouse models of the disease, and whether we could measure this transformation noninvasively through imaging. We developed a PET radiotracer for PKM2 by labeling a PKM2 activator, DASA-23, with carbon-11. DASA-23 has been shown to display selective activation of PKM2 (AC 50 = 90 nM) versus other PK isozymes, PKM1, PKR, and PKL (12). Carbon-11 was selected for radiolabeling DASA-23 to retain its structure and therefore PKM2-binding selectivity.
Here, high [
11 C]DASA-23 tumor cell uptake was measured in culture, with uptake strongly correlated to PKM2 protein expression. Nevertheless, we observed modest nonspecific binding of [ 11 C]DASA-23 to cells with low PKM2 expression, which could reduce tumorto-background contrast in living subjects. Because DASA-based activators are known to reversibly bind to dimeric PKM2 (14) , efflux of the radiotracer from tumor cells after removal of exogenous activity was expected, although this occurred at a relatively slow rate. Of note was the ability of [ 11 C]DASA-23 to measure increased PKM2 expression in cells after prolonged incubation without the replacement of fresh medium (up to 72 hours). Cell adaptation to a reduced nutrient environment, akin to poorly perfused tumors in vivo, hints at an important role for PKM2 in the maintenance of metabolic homeostasis. When glucose is abundant, PKM2 is degraded via acetylation and chaperone-mediated autophagy, a process that is inhibited under nutrient stress (20) . The ability to detect chronically nutrient-deprived cells through PKM2 imaging may provide insights into tumor progression and metastasis, given that these cells are relatively chemoresistant (5) .
Given the promising in vitro uptake profile and relatively high lipophilicity (cLogP = 3.4, ChemDraw Bio 13.0) of Low background radioactivity was detected in the brain after rapid initial uptake and washout, as predicted by the absence of PKM2 expression in this tissue (25) , which was confirmed by our immunohistochemistry results. Indeed, PKM2 expression was exclusively confined to the intracranial tumor, which lacked PKM1. Autoradiographic analysis of tumor sections after saline perfusion, which removed unbound/ intravascular radioactivity from the brain, further confirmed tumorspecific binding of [ (33) , have shown great value for imaging tumors of the brain. The primary aim of our study, however, was to noninvasively measure PKM2 status in these tumors. Given the great interest in targeting PKM2 for cancer therapy (12, 14, 34, 35), we additionally explored the ability of [ 11 C]DASA-23 to report on the binding efficacy of these agents using orthotopically implanted PDX models of glioblastoma multiforme (GBM). In these longitudinal studies, infiltrative GBM39 tumors were clearly delineated by PET, with tumor-specific retention of [ 11 C]DASA-23 abolished after pretreatment of the same animals with a bolus of TEPP-46, a structurally distinct class of PKM2 activators known to bind the same allosteric site as the DASA class of activators (14) . These data provide further evidence of the in vivo specificity of [ 11 C]DASA-23 for reporting on tumor-specific PKM2 expression and a potential role for both drug screening and the evaluation of precision medicine strategies. Furthermore, the observation that temozolomide-treated glioblastomas have reduced PKM2 expression (36) indicates that [ 11 C]DASA-23 may also provide a means to measure the efficacy of more traditional therapeutics.
In conclusion, we have synthesized and evaluated an imaging agent for the measurement of dimeric PKM2, [ 
MATERIALS AND METHODS

Study design
The primary research objective was to design and synthesize an imaging agent to noninvasively measure tumor-specific PKM2 in living subjects via PET. Six to seven animals per group were used for the evaluation of PKM2 in orthotopic models of GBM, calculated with 90% power and a 5% significance level. For TEPP-46 treatment studies, animals were randomized before imaging and subsequent treatment. All outliers were included in the analysis, and no data were excluded. Authors were not blinded to the results. A minimum of three experimental replicates were recorded for all in vitro data.
Cell culture
HeLa cells [American Type Culture Collection (ATCC)] and U87 human glioma cells (ATCC) were grown in Dulbecco's modified Eagle's medium (DMEM; Life Technologies) containing 10% fetal bovine serum, 2 mM L-glutamine, and 2.5 ml of penicillin (100 IU/ml)/ streptomycin (100 mg/ml). GBM39, transfected with a lentiviral vector that expressed a fusion protein of green fluorescent protein (GFP) and firefly luciferase, was received as a gift from P. Mischel (Ludwig Institute for Cancer Research, University of California, San Diego). GBM39 cells were grown in a defined, serum-free medium consisting of a 1:1 mixture of Neurobasal-A medium DMEM/F12 that also contained Hepes buffer solution (10 mM), minimum essential medium (MEM) sodium pyruvate solution (1 mM), MEM nonessential amino acids solution (10 mM) (1×), GlutaMAX-I Supplement (1×), and antibioticantimycotic (1×) from Life Technologies Inc. The full working medium was additionally supplemented with human epidermal growth factor (20 ng/ml), human fibroblast growth factor basic 154 (20 ng/ml), human platelet-derived growth factor (PDGF)-AA (10 ng/ml), human PDGF-BB (10 ng/ml), and heparin solution, 0.2% (2 mg/ml) as growth factors (all from Shenandoah Inc.) and B-27 (Life Technologies Inc.). All cells were propagated at 37°C in a humidified atmosphere containing 5% CO 2 .
Precursor and cold standard synthesis The precursor for radiosynthesis was obtained through the reaction scheme illustrated in Fig. 2A. 1 -(tert-Butyloxycarbonyl)piperazine (1) (1.34 mmol, 1 equiv.) was dissolved in dichloromethane (2.5 ml) under nitrogen and cooled to 0°C. Triethylamine (2.68 mmol, 2.0 equiv.) was added followed by portion-wise addition of 2,6-difluorobenzenesulfonyl chloride (2) (1.48 mmol, 1.1 equiv.). The reaction was stirred at 0°C for 1 hour and quenched with saturated aqueous ammonium chloride solution. The organic layer was washed with brine, dried over sodium sulfate, and concentrated in vacuo. The residue was purified via silica gel chromatography using a 95:5 to 5:95 (v/v) hexane/EtOAc gradient to give tert-butyl 4-((2,6 difluoro-phenyl)-sulfonyl)piperazine-1-carboxylate (3) as white crystals (80% yield).
tert-Butyloxycarbonyl protected compound 3 (1.04 mmol) was dissolved in dichloromethane (1 ml) and cooled to 0°C. TFA (1 ml) was added, and the reaction was monitored by TLC. After the reaction was complete, the solvents were evaporated in vacuo to yield the TFA salt of compound 4 as a light yellow oil, which was carried onto the next step without further purification. The oily residue 4 was dissolved in dichloromethane (2 ml) and cooled to 0°C. Triethylamine (4.16 mmol, 4 equiv.) was added followed by portion-wise addition of 4-hydroxybenzene-1-sulfonyl chloride (1.14 mmol, 1.1 equiv.). The progress of the reaction was monitored via TLC, and once complete, the reaction was quenched with saturated aqueous ammonium chloride solution (3 ml). The organic layer was washed twice with saturated ammonium chloride solution, once with brine, dried over sodium sulfate, and concentrated in vacuo. The resulting product was dissolved in dimethyl sulfoxide and purified by reversed-phase HPLC [Phenomenex Luna C18 column (5 mm, was eluted from the cartridge using ethanol (0.75 ml) and then saline (6.75 ml). The overall synthesis time was 52 min. Analytical HPLC (Phenomenex Gemini C18 5 m, 250 × 4.6 mm, 60% acetonitrile, 40% 0.1 M NH 4 HCO 2 with 0.5% AcOH, 1 ml/min) was used for assessment of radiochemical purity and specific activity.
Cell uptake and efflux studies U87 and HeLa cells (2 × 10 5 ) were plated into six-well plates overnight before [ 11 C]DASA-23 at 37°C and 5% CO 2 over a 60-min time course. At the indicated time points, plates were placed on ice, washed three times with ice-cold phosphatebuffered saline (PBS), and lysed in radioimmunoprecipitation assay buffer (Thermo Fisher Scientific Inc.; 500 ml). Cell lysates (300 ml) were transferred to counting tubes, and decay-corrected radioactivity was determined on a gamma counter (Cobra II Auto-Gamma Counter; Packard Biosciences Co.). The remaining lysate was frozen and used after radioactive decay for protein determination with a bicinchoninic acid (BCA) 96-well plate assay (Thermo Fisher Scientific Inc.) and for immunoblotting. In addition, 10-ml standards from the solution (0.925 MBq/ml) added to cells were counted to quantitate percentage radiotracer uptake. For efflux studies, cells were incubated with radiotracer for 60 min and washed three times with room temperature Hanks' buffered salt solution before subsequent incubation at 37°C in fresh, radiotracer-free DMEM. At the specified times, samples were processed as described above.
PKM2 siRNA PKM2 knockdown in HeLa cells was performed over a time course of 72 hours after transfection. Cells were seeded in six-well plates in antibiotic-free DMEM at 1.5 × 10 6 cells per well 24 hours before siRNA transfection with DharmaFECT1 (Thermo Scientific) according to the manufacturer's instructions. Specific siRNAs targeting only PKM2 were custom-made by Thermo Scientific using the following sequences: CCAUAAUCGUCCUCACCAAUU (sense) and UUGGU-GAGGACGAUUAUGGUU (antisense) (37) . Scrambled siRNA (siCtrl; Cell Signaling Technology) was used as a control. siRNAs were added at a final concentration of 25 nM. [
11 C]DASA-23 uptake (0.925 MBq/ml) was measured after 30 min in cells transfected with siCtrl and siPKM2 at 24, 48, and 72 hours after transfection, after being processed as described in the previous section. Untreated cells were used as a further control, measured 24 hours after addition of fresh DMEM and 96 hours after seeding.
Western blotting
Monoclonal rabbit antibodies to PKM1 and PKM2 (1:1000 dilution, Cell Signaling Technology) were used in a standard Western blotting protocol. A rabbit anti-actin antibody (1:2000, Sigma-Aldrich Co. Ltd.) was used as a loading control. Blots were scanned, and signal was quantified with ImageJ (National Institutes of Health).
In vivo tumor models All experimental procedures involving animals were approved by the Stanford University Institutional Animal Care and Use Committee. For subcutaneous tumor models, U87 tumor cells (5 × 10 6 cells; 100 ml of PBS) were injected subcutaneously on the back of female BALB/c nude mice (aged 6 to 8 weeks; Charles River Laboratories) and grown to~150 mm 3 . Tumor dimensions were measured periodically using a caliper (by the same researcher), with tumor volumes calculated by the following equation: volume = (p/6) × a × b × c, where a, b, and c represent three orthogonal axes of the tumor. For orthotopic brain tumor models, either 2 × 10 5 U87 or 4 × 10 5 GBM39 cells were implanted in the right hemisphere, 0.5 mm anterior and 2 mm lateral to the lambda, in the brains of 6-to 8-week-old nude mice held in place with a stereotaxic unit (Stoelting). The cells, suspended in 4 ml of PBS, were injected at a depth of 3 mm over 5 min with an AS blunt-ended Hamilton syringe, which was subsequently held in place for a further 5 min. Animals were anesthetized with an intraperitoneal injection of ketamine (150 mg/kg) and xylazine (15 mg/kg). U87 tumor-bearing mice were subsequently imaged by MRI and PET 32 to 35 days after intracranial injection, and GBM39 tumor-bearing mice were imaged between 44 and 50 days after implantation. For blocking studies, mice were imaged with [ Imaging studies MRI was performed at the Stanford Clark Center Small Animal Imaging Facility in an actively shielded Discovery MR901 General Electric 7T horizontal bore scanner (GE Healthcare) including Integrated Electronics Company gradient drivers, an Agilent 120-mm-inner diameter shielded gradient insert (600 mT/m, 1000 T/m/s), EXCITE2 electronics, the supporting LX11 platform, and a 3-cm-inner diameter Millipede quadrature transmit/receive volume RF coil. Animals were anesthetized with 2% isoflurane in oxygen, and physiological monitoring included respiration and temperature feedback for maintaining surface body temperature by warm airflow over the animal. A fast spoiled gradient echo sequence (repetition time, 9.7 ms; echo time, 2.1 ms; flip angle, 5°; number of excitations, 20; field of view, 2 cm; image matrix, 160 × 160; slice thickness, 1 mm) was used to acquire three sets of 12, 12, and 8 orthogonal T 1 -weighted images in the axial, sagittal, and coronal planes through the mass, respectively. PET/MR registration was performed in IRW (Siemens) using the CT image for alignment of the skull.
PET imaging scans were carried out on a docked Siemens Inveon PET/CT scanner (matrix size, 128 × 128 × 159; CT attenuation-corrected; nonscatter-corrected) after a bolus intravenous injection of~18.5 MBq of [ 
Ex vivo biodistribution
After the PET imaging studies, 60 min after radiotracer administration, mice were sacrificed by exsanguination via cardiac puncture and tissues were harvested. Tissue radioactivity for all organs was subsequently determined on a gamma counter (decay-corrected; Cobra II AutoGamma Counter, Packard Biosciences Co.). Ten-microliter standards from the stock activity were also counted for data normalization. Data were expressed as % ID/g.
Ex vivo autoradiography
Autoradiography was performed as in (38) . In brief, coronal brain sections of U87 and GBM39 tumor-bearing mice were obtained 20 min after intravenous injection of 26 MBq [ 11 C]DASA-23. Anesthetized mice were perfused with saline (10 ml) to remove intravascular [ 11 C]DASA-23, and after cervical dislocation, the brain was removed and embedded in optimal cutting temperature (OCT) compound (Tissue-Tek) before being frozen on dry ice. Subsequently, 10-mm-thick coronal brain sections were cut with a cryostat microtome HM 500 (Microm). The sections were mounted on microscope slides (Fisherbrand Superfrost Plus microscope slides), air-dried for a minimum of 5 min, and then exposed to MultiSensitive storage phosphor screens (PerkinElmer) for 3 hours at −20°C. The image plates were analyzed with a Typhoon 9410 variable mode imager (Amersham Biosciences), and image data were visualized and processed by ImageJ.
Plasma stability [ 11 C]DASA-23 stability in mouse plasma was assessed ex vivo according to previously described methodology (38) . Samples were incubated for 10, 30, and 60 min and compared to a standard from the respective injected radiotracer formulation.
Histopathology
After imaging, anesthetized mice bearing orthotopically implanted U87 tumors were transcardially perfused with 0.9% saline, followed by the removal of the brain. Formalin-fixed brains (10%, v/v) were embedded in paraffin, coronally sectioned into 5-mm-thick slices, and mounted on microscope slides according to standard procedures (Histo-Tec Laboratory). Sections were taken at regular intervals across the entire brain. Every sixth section was stained with H&E (Histo-Tec Laboratory). Immunohistochemistry against PKM1 and PKM2 was performed on paraffin-embedded sections with rabbit monoclonal antibodies reactive to both mouse and human isozymes (1:100, Cell Signaling Technology) using standard techniques and according to the manufacturer's instructions (Cell Signaling Technology). Before staining, antigen retrieval was performed in 10 mM sodium citrate buffer at 90°C for 10 min. For detection, VECTASTAIN Elite ABC and Vector NovaRED (Vector Laboratories) were used per the manufacturer's recommendations. Histopathological staining (H&E and PKM2) of fresh-frozen sections taken for autoradiography was processed using standard techniques and according to the manufacturer's instructions (Cell Signaling Technology).
Statistical analysis
Data were expressed as means ± SD. Statistical significance was determined using a two-tailed Student's t test. Paired t tests were used for longitudinal studies (Fig. 6E) , with unpaired t tests used to derive significance for all other analyses. For the analysis of [
11 C]DASA-23 uptake in multiple tissues, significance was determined by analysis of variance (ANOVA), followed by Tukey's honest significant difference test. Correlation analysis using Spearman's rank correlation, linear regression, statistical significance, and 95% confidence levels was determined using Prism software for Mac OSX (v.6.0e; GraphPad Software). Differences between groups were considered significant if P ≤ 0.05.
SUPPLEMENTARY MATERIALS
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